Linked Life Data

2650879

Source:http://linkedlifedata.com/resource/pubmed/id/2650879

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1989-5-31
pubmed:abstractText
Naproxen was compared with placebo in a double-blind, crossover trial in classic and common migraine. The trial was terminated at a fixed date; 37 patients had entered, 5 of whom were excluded. Naproxen was given as 750 mg at the first symptom of the attack, a total of 1250 mg per 24 h was allowed. Patients were followed for six attacks or three months in each phase, whichever came first. The severity of the headache was significantly less with naproxen in the first 2 h of the attack (p = 0.047), whereas there was no difference when the whole attack was considered. Significantly more patients preferred naproxen (p = 0.042). Side effects occurred in five patients, causing withdrawal of one patient while on naproxen.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0333-1024
pubmed:author
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
29-32
pubmed:dateRevised
2008-2-11
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks.
pubmed:affiliation
Department of Neuromedicine, Hjørring Sygehus, Denmark.
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial